main menu

Pages

Abb Vie Ordered to Pay $150 Million Damages in `Low T' Trial

First AndroGel (Low-Testosterone) Trial: $150M Verdict

Abb Vie Ordered to Pay $150 Million Damages in `Low T' Trial

AbbVie Inc. was ordered to pay $150 million to an Oregon man who accused the drugmaker of hiding the heart-attack risks of its AndroGel testosterone booster, but the company’s first trial loss probably won’t stand because jurors awarded no compensation for injuries.